migraine disorders/니코틴

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT Not Applicable REFERENCE TO SEQUENCE LISTING, A TABLE, OR A COMPUTER PROGRAM LISTING COMPACT DISC APPENDIX Not Applicable BACKGROUND The present formulation relates to the field of pharmaceutical treatments for pain and in particular to

TECHNICAL FIELD Embodiments disclosed herein generally relate to a method of treatment for weight-loss and other conditions in a mammal. More particularly, embodiments herein are directed to anatomically targeted, low-dosage delivery of antiepileptic/anticonvulsant compounds for weight-loss and

BACKGROUND OF THE INVENTION Certain adamantane derivatives have been used to treat illnesses. Rimantadine (1-(1-aminoethyl)adamantane) is used for the prophylaxis and treatment of influenza in humans. Amantadine has been used for the treatment of both influenza and Parkinson's disease (Schwab et

BACKGROUND OF THE INVENTION Certain adamantane derivatives have been used to treat illnesses. Rimantadine (1-(1-aminoethyl)adamantane) is used for the prophylaxis and treatment of influenza in humans. Amantadine has been used for the treatment of both influenza and Parkinson's disease (Schwab et

BACKGROUND OF THE INVENTION Certain adamantane derivatives have been used to treat illnesses. Rimantadine (1-(1-aminoethyl)adamantane) is used for the prophylaxis and treatment of influenza in humans. Amantadine has been used for the treatment of both influenza and Parkinson's disease (Schwab et

This invention relates to an optically pure morpholinol, pharmaceutical formulations containing it and processes for their preparation and use. BACKGROUND OF THE INVENTION Bupropion hydrochloride, (.+-.)-1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)-amino]-1-propanone hydrochloride, is the active

This invention relates to an optically pure morpholinol, pharmaceutical formulations containing it and processes for their preparation and use. BACKGROUND OF THE INVENTION Bupropion hydrochloride, (.+-.)-1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)-amino]-1-propanone hydrochloride, is the active

BACKGROUND OF THE INVENTION Bupropion hydrochloride, (.+-.)-1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)-amino]-1-propanone hydrochloride, is the active ingredient of Wellbutrin.RTM. which is marketed in the United States for the treatment of depression. It is also the active ingredient of Zyban.RTM.

BACKGROUND OF THE INVENTION Bupropion hydrochloride, (.+-.)-1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)-amino]-1-propanone hydrochloride, is the active ingredient of Wellbutrin.RTM. which is marketed in the United States for the treatment of depression. It is also the active ingredient of Zyban.RTM.

BACKGROUND OF THE INVENTION Serotonin (5-hydroxy-tryptamine) (5-HT) receptors play an important role in many physiological and pathological functions like anxiety, sleep regulation, aggression, feeding and depression. The 5-HT receptors are distributed throughout the body and can be divided is into

This invention relates to an optically pure morpholinol, salts and solvates thereof, pharmaceutical formulations containing them and processes for their preparation and use. BACKGROUND OF THE INVENTION Bupropion hydrochloride, (.+-.)-1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)-amino]-1-propanone

This invention relates to a cocoa extract and to its uses. In particular, the invention relates to uses for cocoa extracts in the treatment and prophylaxis of, for example, depression, anxiety or addiction, and for mood enhancement. Chocolate and cocoa are popularly claimed to have a plethora of

BACKGROUND OF THE INVENTION Neuronal nicotinic acetylcholine receptors (nAChRs) serve a wide range of physiological functions and have been implicated in a number of pathological processes and pharmacological effects of nicotinic drugs. Many of the important in vivo effects of nicotine in the

BACKGROUND OF THE INVENTION Neuronal nicotinic acetylcholine receptors (nAChRs) serve a wide range of physiological functions and have been implicated in a number of pathological processes and pharmacological effects of nicotinic drugs. Many of the important in vivo effects of nicotine in the

BACKGROUND OF THE INVENTION Neuronal nicotinic acetylcholine receptors (nAChRs) are ligand-gated cation channels in the central nervous system (CNS) and the peripheral nervous system (PNS). The nAChRs serve a wide range of physiological functions, and have been implicated in a number of pathological